about
Signal initiation in biological systems: the properties and detection of transient extracellular protein interactions.Anti-idiotypic protein domains selected from protein A-based affibody libraries.Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIVEC4, a truncation of soluble N-cadherin, reduces vascular smooth muscle cell apoptosis and markers of atherosclerotic plaque instability.The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.The challenges involved in elucidating the molecular basis of sperm-egg recognition in mammals and approaches to overcome them.Agents under investigation for the treatment and prevention of neutropenia.A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia.Neutralization of hepatitis A virus (HAV) by an immunoadhesin containing the cysteine-rich region of HAV cellular receptor-1.Immunoadhesins containing pre-S domains of hepatitis B virus large envelope protein are secreted and inhibit virus infection.Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin.Expression and characterization of a DNase I-Fc fusion enzyme.A hingeless Fc fusion system for site-specific cleavage by IdeSTRKB signalling controls the expression of N-methyl-d-aspartate receptors in the visual cortex.Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor.The Ephrin-A5/EphA4 Interaction Modulates Neurogenesis and Angiogenesis by the p-Akt and p-ERK Pathways in a Mouse Model of TLE.Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis.Non-Antibody Scaffolds as Alternative Therapeutic Agents
P2860
Q30474052-4BF6EE76-AFC7-4523-A2D5-931E3D71CEA4Q30835904-212C95F8-C784-40DE-983D-972586EAD891Q34034670-A8ACA2F9-801A-48C4-809E-FBFBA777041EQ34761889-53F648E5-5A73-4D93-ACD5-2C9CBA490635Q34939533-A8027501-E9F0-47A0-9D1E-09FE8A35F019Q35184213-1D4EA62F-AA8D-4E54-9037-48C11779A754Q35669849-90151AEF-9094-4760-A628-425174D8B7A6Q36427079-1504218B-B62A-4D86-81E5-5603AAFBD8CDQ36985881-6422B78A-96CE-4E41-9A1F-A74E04D0748BQ38014356-28433E3E-4865-473E-B110-8B60AF09B734Q39601471-588285D0-FF19-4EEB-A60D-2C5541670974Q40165285-CE8AAF63-A4A8-409F-8D8A-96022B4DB186Q41020913-EEF38623-1752-4015-8246-79DAB483CFF9Q41041346-2B484DA5-9DD5-4997-BBD7-562984CFA43FQ41616388-AFB4D7EC-69B9-4B14-BA18-4BE62F6DE984Q42390719-8984609C-F56A-4E1D-9CBA-6D59ADAE96FFQ44182022-399627C8-5A13-4DF1-8ADB-8B5038B57CD9Q46693604-CE72D4A0-03CF-4E1D-B07E-7D4A2271A24EQ48414222-039D681B-BC99-41B0-9EE6-965332EE6DBBQ51818158-F962832A-F35F-462E-80B7-3A7874607246Q57260221-764BB4C3-F5A9-4BA8-82B5-E059DB630031
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Immunoadhesins: principles and applications.
@en
type
label
Immunoadhesins: principles and applications.
@en
prefLabel
Immunoadhesins: principles and applications.
@en
P1476
Immunoadhesins: principles and applications.
@en
P2093
Ashkenazi A
P356
10.1016/0167-7799(96)80921-8
P577
1996-02-01T00:00:00Z